Last reviewed · How we verify
Sotradecol (SODIUM TETRADECYL SULFATE)
Sotradecol (Sodium Tetradecyl Sulfate) is a small molecule drug in the tetradecyl sulfate class, originally developed by Elkins Sinn and currently owned by the same company. It was FDA-approved in 1946 for the treatment of venous varices. As an off-patent medication, Sotradecol is available as a generic product from multiple manufacturers. Key safety considerations include the potential for local irritation and allergic reactions. Sotradecol is used to reduce the appearance of varicose veins.
At a glance
| Generic name | SODIUM TETRADECYL SULFATE |
|---|---|
| Sponsor | Elkins Sinn |
| Drug class | tetradecyl sulfate |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1946 |
Approved indications
- Venous varices
Common side effects
- Anaphylactic shock
- Myocardial infarction
- Cerebrovascular accident
- Fatal pulmonary embolism
- Death
- Headache
- Nausea
- Vomiting
- Urticaria
- Ulceration
- Pain
- Asthma
Key clinical trials
- Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias (PHASE4)
- Pilot RCT Evaluating a One Stop Vein Clinic (NA)
- Investigation Into the Pathophysiology and Treatment of Varicose Veins (NA)
- Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations (PHASE4)
- Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding (PHASE3)
- Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia (NA)
- Laser Ablation Versus Mechanochemical Ablation Trial (PHASE4)
- Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sotradecol CI brief — competitive landscape report
- Sotradecol updates RSS · CI watch RSS
- Elkins Sinn portfolio CI